Published online 20 February 2008
Haematologica, Vol 93, Issue 3, 455-458 doi:10.3324/haematol.12184
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Cheikh, J.
Right arrow Articles by Mohty, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Cheikh, J.
Right arrow Articles by Mohty, M.

Multiple Myeloma

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

Jean El-Cheikh1, Mauricette Michallet2, Arnon Nagler3, Hugues de Lavallade1, Franck E. Nicolini2, Avichai Shimoni3, Catherine Faucher1, Mohamad Sobh2, Daniela Revesz2, Izhar Hardan3, Sabine Fürst1, Didier Blaise1,4, Mohamad Mohty1,4,

1 Unité de Transplantation et de Thérapie Cellulaire (UTTC), Institut Paoli-Calmettes, Marseille, France
2 Hôpital E. Herriot, Service d’hématologie, CHU de Lyon, Lyon, France
3 Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
4 Université de la Méditerranée, Marseille, France

Correspondence: Mohamad Mohty, UTTC, Institut Paoli-Calmettes, 232 Bd. Sainte Marguerite, 13273 Marseille Cedex 09, France. E-mail: mohtym{at}marseille.fnclcc.fr

We describe the results of 37 myeloma patients who received bortezomib following reduced intensity allogeneic stem cell transplantation (RIC-allo-SCT). Grade 1–2 peripheral neuropathy (35%), mild thrombocytopenia (24%) and fatigue (19%) were the most frequent adverse events, while there was no worsening of graft-vs-host disease symptoms. Twenty-seven patients (73%; 95% CI, 59–87%) achieved an objective response. With a median follow-up of 9 months from bortezomib initiation, the estimate of overall survival was 65% at 18 months while this was significantly higher (p=0.002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.

Key words: bortezomib, allogeneic stem cell transplantation, multiple myeloma.




This article has been cited by other articles:


Home page
 BloodHome page
M. Rotta, B. E. Storer, F. Sahebi, J. A. Shizuru, B. Bruno, T. Lange, E. D. Agura, P. A. McSweeney, M. A. Pulsipher, P. Hari, et al.
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Blood, April 2, 2009; 113(14): 3383 - 3391.
[Abstract] [Full Text] [PDF]